Boule Diagnostics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 10, 2022 at 01:30 am EST
Share
Boule Diagnostics AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was SEK 125.6 million compared to SEK 111.8 million a year ago. Net income was SEK 2.4 million compared to SEK 7.1 million a year ago. Basic earnings per share from continuing operations was SEK 0.12 compared to SEK 0.37 a year ago. Diluted earnings per share from continuing operations was SEK 0.12 compared to SEK 0.36 a year ago.
For the nine months, sales was SEK 398.9 million compared to SEK 323.1 million a year ago. Net income was SEK 9.8 million compared to SEK 6 million a year ago. Basic earnings per share from continuing operations was SEK 0.51 compared to SEK 0.31 a year ago. Diluted earnings per share from continuing operations was SEK 0.49 compared to SEK 0.3 a year ago.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
